
Lindsey Groff, PharmD, BCIDP
612 posts

Lindsey Groff, PharmD, BCIDP
@Lingroff9
Infectious Diseases Pharmacy Specialist; PGY1 RPC- @UnivHealthSA. PGY1 / PGY2 ID- @OSUWexMed. PharmD- @UTexasPharmacy.


With the opening of the new University Hospital, we are so excited to share we are also recruiting for another inpatient ID pharmacy team member to join ASP, rounds, research, and teaching @OSUWexMed! Apply today!!! 🦠 #IDTwitter #TwitteRx careers.wexnermedical.osu.edu/search/jobdeta…







🔥Just published 🔥 TAPER-V RCT Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides difficile Infection In this randomized clinical trial of 256, a 4-week vancomycin pulse and taper regimen *had a probability of 74% to be superior to astandard 2-week pulse regimen in patients a first episode or first recurrence of CDI *All patients received 14d pulse of vanco (standardized at 125 mg orally 4 times a day at the time of recruitment) →taper (125 mg q12h ×7d,then 125mg q24h ×7d) vs placebo for management of CDI (first episode or recurrence). Vanco for 10d is obsolete! #IDXposts jamanetwork.com/journals/jaman…



🆕💫 Retrospective, multicenter cohort study(N: 367) Cefdinir was independently associated with treatment failure with nearly twice as high of failure rate compared with cephalexin for the treatment of outpatient uncomplicated UTI #IDXposts #UTIWiki academic.oup.com/ofid/article/1…














